Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.91 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.91 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.91 |
| ▸ | FGFR3 | P22607 | 15/20 | 0.91 |
| ▸ | KDR | P35968 | 11/20 | 0.91 |
| ▸ | FLT1 | P17948 | 10/20 | 0.91 |
| ▸ | FLT4 | P35916 | 10/20 | 0.91 |
| ▸ | SRC | P12931 | 4/20 | 0.91 |
| ▸ | GLA | P06280 | 1/20 | 0.91 |
| ▸ | CSK | P41240 | 1/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.91 |
| ▸ | ATM | Q13315 | 1/20 | 0.91 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | PRKCG | P05129 | 1/20 | 0.66 |
| ▸ | PRKCB | P05771 | 1/20 | 0.66 |
| ▸ | PRKCA | P17252 | 1/20 | 0.66 |
| ▸ | PRKCH | P24723 | 1/20 | 0.66 |
| ▸ | PRKCI | P41743 | 1/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-173074 SCHEMBL29828472 | 0.95 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL177946 | 0.95 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22144559 | 0.93 | FGFR1 (0.95) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30197743 | 0.93 | FGFR1 (0.81) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL17814860 | 0.92 | FGFR1 (0.90) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL12882038 | 0.91 | FGFR1 (0.77) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19338070 | 0.91 | FGFR1 (0.75) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15624527 | 0.90 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL3479994 | 0.88 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL21780972 | 0.88 | FGFR1 (0.85) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160095842-A1 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | MET, FGFR3, FGFR1 | FGFR1 3/4885FGFR2 4/4885FGFR4 9/4885 |
| US-20160095842-A1 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER | FGFR3, FGFR1, PIK3CA | FGFR1 2/4885FGFR2 4/4885FGFR4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.